



Thyas Co. Ltd.



OncoTherapy  
Science, Inc.

**Thyas Co. Ltd. announces licensing agreement with OncoTherapy Science Inc. for development of autologous immunotherapy using iPS cell-derived killer T cells against Oncotherapy Science Inc.-owned peptide vaccines**

June 18, 2019 – Kyoto, Japan

Thyas Co. Ltd. (Thyas), a start-up biotechnology company, announced that OncoTherapy Science Inc. (TSE Mothers: OTS), a clinical stage biotechnology company, has granted Thyas a license to develop a novel autologous immunotherapy using iPS cell (iPSC)-derived killer T cells against OTS-owned peptide vaccines. Under the agreement, Thyas has obtained worldwide exclusive rights to utilize the peptide vaccines for manufacturing the iPS cell-derived killer T cells. Thyas will pay ongoing licensing fees to OTS. The financial terms of the agreement and the target diseases/antigens have not been disclosed.

OTS' peptide vaccines demonstrated positive early clinical results in patients with refractory solid tumors. The peptide vaccines were well tolerated, induced a certain antigen-specific CTL response in many patients, and produced good disease-control rates. The results of the trial demonstrated that the specific CTLs induced by the peptide vaccines infiltrated tumor tissue, and that use of the peptide vaccines effectively enhanced immune responses against such antigen positive cancers.

Thyas' proprietary technology generates iPS cell-derived killer T cells with potent killing and highly proliferative activities. When combined with OTS' peptide vaccines, Thyas has the potential to precisely direct iPSC-derived killer T cells to antigen-positive cancers, yielding improved clinical activity against many cancer types that express the antigen. Thyas' future clinical studies will investigate this capability in the presence of measurable residual or recurrent cancers.

**About OTS**

OTS has been developing innovative anti-cancer medicines and cancer-specific serum diagnostic markers using cancer-specific genes/proteins, which are do not occur naturally in organs or tissues. The company has multiple pipelines in clinical development worldwide and several discovery programs.

OTS contact: <https://www.oncotherapy.co.jp/en/contact-us/form1>

**About Thyas**

Thyas is a startup company based on the technologies developed at the Center for iPS cell Research and Application, Kyoto University, Japan, and supported by Kyoto University Innovation Capital Co. Ltd., a wholly owned investment firm of the university. The company has been developing autologous immunotherapy with iPSC-derived killer T cells to cure patients suffering from deadly diseases. The technology was established by Dr. Shin Kaneko, an associate professor and a leading scientist of immunotherapy using iPSC-derived killer T cells, at the Center for iPS cell Research and Application, Kyoto University, and has been licensed to Thyas for development of autologous immunotherapy. The iPSC technology allows Thyas to stably supply a large quantity of tumor-specific or virus-specific T cells that have high proliferative capacity and potent killing activity.

Thyas contact: <http://thyas.com/inquiry/>